Skip to content
S8038Senate2023-2024 SessionSame asA8501

Clarify Step Therapy Notices

Official title

“Relates to adverse determinations related to a step therapy protocol override determination; repealer”

Sponsor Neil D. BreslinSD-46
Status
Senate Floor Calendar
Impact
6/10
Moderate
Outcome
Companion signed

Bill progress

Signed via A8501

What's happening

This bill updates insurance and public health laws to clarify the required content and delivery of adverse step therapy protocol determination notices.

Why it matters

  1. Enhances transparency for patients and providers. The bill requires that adverse determinations regarding step therapy protocol overrides must specify the clinical review criteria used, as well as any alternative drugs considered, making it clearer why a medication was denied and what alternatives exist.

  2. Improves guidance for appeals. Notices must now detail any additional information needed for appeals, potentially reducing delays and confusion for patients and providers trying to challenge coverage denials.

  3. Modernizes communication methods. Health plans and utilization review agents are explicitly allowed to issue these adverse determination notices electronically, including via email or secure online portals. This could speed up notification times and make it easier for members and providers to access important information.

  4. Aligns insurance and public health law processes. By amending both insurance and public health laws to mirror each other, the bill creates a more consistent regulatory framework for how step therapy-related adverse determinations are communicated across different types of health plans.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Clarify Step Therapy Notices

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Neil D. Breslin

Senator · Senate District 46

Chair, Ethics And Internal GovernanceChair, Insurance

No co-sponsors yet.

History

  1. Substituted by A8501
  2. Ordered to third reading cal.38
  3. Referred to rules

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A8501Assembly

Clarify Step Therapy Notices

Signed by Governor · Sponsor John T. McDonald III

Impact 6 · ModerateSigned into law

Full text

4 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

8038

IN SENATE

January 5, 2024

Introduced by Sen. BRESLIN -- read twice and ordered printed, and when printed to be committed to the Committee on Rules

AN ACT to amend the insurance law and the public health law, in relation to adverse determinations related to a step therapy protocol override determination; and to repeal certain provisions of the insurance law and the public health law relating thereto

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Paragraph 14 of subsection (a) of section 4902 of the insurance law, as added by a chapter of the laws of 2023 amending the insurance law and the public health law relating to requiring notice of adverse step therapy determinations, as proposed in legislative bills numbers S. 2677-A and A. 463-A, is REPEALED.

§ 2. Paragraph 5 of subsection (a) of section 4902 of the insurance law, as added by chapter 705 of the laws of 1996, subparagraph (ii) as amended by chapter 586 of the laws of 1998, is amended to read as follows:

(5) (i) Establishment of a written procedure to assure that the notice of an adverse determination includes:

[(i)] (A) the reasons for the determination including the clinical rationale, if any;

[(ii)] (B) instructions on how to initiate standard and expedited appeals pursuant to section four thousand nine hundred four of this article and an external appeal pursuant to section four thousand nine hundred fourteen of this article; [and

(iii)] (C) notice of the availability, upon request of the insured or the insured's designee, of the clinical review criteria relied upon to make such determination;

(D) what, if any, additional necessary information must be provided to, or obtained by, the utilization review agent in order to render a decision on appeal; and

(E) for an adverse determination related to a step therapy protocol override determination, information that includes the clinical review criteria relied upon to make such determination and any applicable

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD02500-04-4

alternative prescription drugs subject to the step therapy protocol of the utilization review agent.

(ii) A utilization review agent may provide a notice of an adverse determination related to a step therapy protocol override determination electronically pursuant to subsection (i) of section four thousand nine hundred three of this title, including by electronic mail or through the health care plan's member portal and provider portal. An electronic notice of such an adverse determination may meet the requirements of clause (E) of subparagraph (i) of this paragraph by linking to information posted on the website of the health care plan;

§ 3. Subsection (e-1) of section 4903 of the insurance law, as added by a chapter of the laws of 2023 amending the insurance law and the public health law relating to requiring notice of adverse step therapy determinations, as proposed in legislative bills numbers S. 2677-A and A. 463-A, is REPEALED.

§ 4. Subsection (e) of section 4903 of the insurance law, as added by chapter 705 of the laws of 1996, paragraph 2 as amended by chapter 586 of the laws of 1998, is amended to read as follows:

(e) (1) Notice of an adverse determination made by a utilization review agent shall be in writing and must include:

[(1)] (i) the reasons for the determination including the clinical rationale, if any;

[(2)] (ii) instructions on how to initiate standard appeals and expedited appeals pursuant to section four thousand nine hundred four and an external appeal pursuant to section four thousand nine hundred fourteen of this article; [and

(3)] (iii) notice of the availability, upon request of the insured, or the insured's designee, of the clinical review criteria relied upon to make such determination. Such notice shall also specify what, if any, additional necessary information must be provided to, or obtained by, the utilization review agent in order to render a decision on the appeal; and

(iv) for an adverse determination related to a step therapy protocol override request, information that includes the clinical review criteria relied upon to make such determination and any applicable alternative prescription drugs subject to the step therapy protocol of the utilization review agent.

(2) A utilization review agent may provide notice of an adverse determination related to a step therapy protocol override determination electronically pursuant to subsection (i) of this section, including by electronic mail or through the health care plan's member portal and provider portal. An electronic notice of such an adverse determination may meet the requirements of subparagraph (iv) of paragraph one of this subsection by linking to information posted on the website of the health care plan.

§ 5. Paragraph (l) of subdivision 1 of section 4902 of the public health law, as added by a chapter of the laws of 2023 amending the insurance law and the public health law relating to requiring notice of adverse step therapy determinations, as proposed in legislative bills numbers S. 2677-A and A. 463-A, is REPEALED.

§ 6. Paragraph (e) of subdivision 1 of section 4902 of the public health law, as added by chapter 705 of the laws of 1996, subparagraph (ii) as amended by chapter 586 of the laws of 1998, is amended to read as follows:

(e) (i) Establishment of a written procedure to assure that the notice of an adverse determination includes: [(i)] (1) the reasons for the determination including the clinical rationale, if any; [(ii)] (2) instructions on how to initiate standard and expedited appeals pursuant to section forty-nine hundred four and an external appeal pursuant to section forty-nine hundred fourteen of this article; [and (iii)] (3) notice of the availability, upon request of the enrollee or the enrollee's designee, of the clinical review criteria relied upon to make such determination; (4) what, if any, additional necessary information must be provided to, or obtained by, the utilization review agent in order to render a decision on an appeal; and (5) for an adverse determination related to a step therapy protocol override determination, information that includes the clinical review criteria relied upon to make such determination and any applicable alternative prescription drugs subject to the step therapy protocol of the utilization review agent.

(ii) A utilization review agent may provide notice of an adverse determination related to a step therapy protocol override determination electronically pursuant to subdivision nine of section forty-nine hundred three of this title, including by electronic mail or through the health care plan's member portal and provider portal. An electronic notice of such an adverse determination may meet the requirements of clause five of subparagraph (i) of this paragraph by linking to information posted on the website of the health care plan;

§ 7. Subdivision 5-a of section 4903 of the public health law, as added by a chapter of the laws of 2023 amending the insurance law and the public health law relating to requiring notice of adverse step therapy determinations, as proposed in legislative bills numbers S. 2677-A and A. 463-A, is REPEALED.

§ 8. Subdivision 5 of section 4903 of the public health law, as added by chapter 705 of the laws of 1996, paragraph (b) as amended by chapter 586 of the laws of 1998, is amended to read as follows:

5. (a) Notice of an adverse determination made by a utilization review agent shall be in writing and must include:

[(a)] (i) the reasons for the determination including the clinical rationale, if any;

[(b)] (ii) instructions on how to initiate standard and expedited appeals pursuant to section forty-nine hundred four and an external appeal pursuant to section forty-nine hundred fourteen of this article; [and

(c)] (iii) notice of the availability, upon request of the enrollee, or the enrollee's designee, of the clinical review criteria relied upon to make such determination. Such notice shall also specify what, if any, additional necessary information must be provided to, or obtained by, the utilization review agent in order to render a decision on the appeal; and

(iv) for an adverse determination related to a step therapy protocol override request, information that includes the clinical review criteria relied upon to make such determination and any applicable alternative prescription drugs subject to the step therapy protocol of the utilization review agent.

(b) A utilization review agent may provide notice of an adverse determination related to a step therapy protocol override determination electronically pursuant to subdivision nine of this section, including by electronic mail or through the health care plan's member portal and provider portal. An electronic notice of such an adverse determination may meet the requirements of subparagraph (iv) of paragraph (a) of this subdivision by linking to information posted on the website of the health care plan.

§ 9. This act shall take effect on the same date and in the same manner as a chapter of the laws of 2023 amending the insurance law and the public health law relating to requiring notice of adverse step therapy determinations, as proposed in legislative bills numbers S. 2677-A and A. 463-A, takes effect.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law and the public health law, in relation to adverse determinations related to a step therapy protocol override determination; and to repeal certain provisions of the insurance law and the public health law relating thereto

Purpose

This is a chapter amendment that makes changes to provisions of L.2023, c.735, to require notice of adverse step therapy determinations.

Summary of provisions

This legislation requires insurers to share additional information with consumers when delivering notices of adverse step therapy determinations and allows electronic delivery of such notices.

Justification

This legislation is a negotiated change to the underlying chapter.

Legislative history

Chapter Amendment to Chapter 735 of the Laws of 2023. 5.2677A and A.463A both passed the Senate and Assembly in June 2023.

Fiscal implications

None

Effective date

This act shall take effect on the same date and in the same manner as a Chapter of the Laws of 2023 amending the Insurance Law and the Public Health La relating to requiring notice of adverse step therapy determi- nations, as proposed in legislative bills numbers S.2677-A and A.463-A, takes effect.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.